Blocking a newly identified memory pathway could prevent the disorder
About 8 million Americans suffer from nightmares and flashbacks to a traumatic event. This condition, known as post-traumatic stress disorder (PTSD), is particularly common among soldiers who have been in combat, though it can also be triggered by physical attack or natural disaster.
Studies have shown that trauma victims are more likely to develop PTSD if they have previously experienced chronic stress, and a new study from MIT may explain why. The researchers found that animals who underwent chronic stress prior to a traumatic experience engaged a distinctive brain pathway that encodes traumatic memories more strongly than in unstressed animals.
Blocking this type of memory formation may offer a new way to prevent PTSD, says Ki Goosens, the senior author of the study, which appears in the journal Biological Psychiatry.
“The idea is not to make people amnesic but to reduce the impact of the trauma in the brain by making the traumatic memory more like a ‘normal,’ unintrusive memory,” says Goosens, an assistant professor of neuroscience and investigator in MIT’s McGovern Institute for Brain Research.
The paper’s lead author is former MIT postdoc Michael Baratta.
Strong memories
Goosens’ lab has sought for several years to find out why chronic stress is so strongly linked with PTSD. “It’s a very potent risk factor, so it must have a profound change on the underlying biology of the brain,” she says.
To investigate this, the researchers focused on the amygdala, an almond-sized brain structure whose functions include encoding fearful memories. They found that in animals that developed PTSD symptoms following chronic stress and a traumatic event, serotonin promotes the process of memory consolidation. When the researchers blocked amygdala cells’ interactions with serotonin after trauma, the stressed animals did not develop PTSD symptoms. Blocking serotonin in unstressed animals after trauma had no effect.
“That was really surprising to us,” Baratta says. “It seems like stress is enabling a serotonergic memory consolidation process that is not present in an unstressed animal.”
Memory consolidation is the process by which short-term memories are converted into long-term memories and stored in the brain. Some memories are consolidated more strongly than others. For example, “flashbulb” memories, formed in response to a highly emotional experience, are usually much more vivid and easier to recall than typical memories.
Goosens and colleagues further discovered that chronic stress causes cells in the amygdala to express many more 5-HT2C receptors, which bind to serotonin. Then, when a traumatic experience occurs, this heightened sensitivity to serotonin causes the memory to be encoded more strongly, which Goosens believes contributes to the strong flashbacks that often occur in patients with PTSD.
“It’s strengthening the consolidation process so the memory that’s generated from a traumatic or fearful event is stronger than it would be if you don’t have this serotonergic consolidation engaged,” Baratta says.
“This study is a very nice dissection of the mechanism by which chronic stress seems to activate new pathways not seen in unstressed animals,” says Mireya Nadal-Vicens, medical director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, who was not part of the research team.
Drug intervention
This memory consolidation process can take hours to days to complete, but once a memory is consolidated, it is very difficult to erase. However, the findings suggest that it may be possible to either prevent traumatic memories from forming so strongly in the first place, or to weaken them after consolidation, using drugs that interfere with serotonin.
“The consolidation process gives us a window in which we can possibly intervene and prevent the development of PTSD. If you give a drug or intervention that can block fear memory consolidation, that’s a great way to think about treating PTSD,” Goosens says. “Such an intervention won’t cause people to forget the experience of the trauma, but they might not have the intrusive memory that is ultimately going to cause them to have nightmares or be afraid of things that are similar to the traumatic experience.”
The Food and Drug Administration has already approved a drug called agomelatine that blocks this type of serotonin receptor and is used as an antidepressant.
Such a drug might also be useful to treat patients who already suffer from PTSD. These patients’ traumatic memories are already consolidated, but some research has shown that when memories are recalled, there is a window of time during which they can be altered and reconsolidated. It may be possible to weaken these memories by using serotonin-blocking drugs to interfere with the reconsolidation process, says Goosens, who plans to begin testing that possibility in animals.
The findings also suggest that the antidepressant Prozac and other selective serotonin reuptake inhibitors (SSRIs), which are commonly given to PTSD patients, likely do not help and may actually worsen their symptoms. Prozac enhances the effects of serotonin by prolonging its exposure to brain cells. While this often helps those suffering from depression, “There’s no biological evidence to support the use of SSRIs for PTSD,” Goosens says.
Read more: Possible new weapon against PTSD
The Latest on: PTSD Cure
[google_news title=”” keyword=”PTSD Cure” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: PTSD Cure
- First responders can now file PTSD under workers comp under new OK lawon May 9, 2024 at 3:30 pm
Employers can be required to pay up to $10,000 for treatment as well. LOCAL NEWS: OKC City council moves forward with proposed hotel tax increase Nelson called it a big step in eroding the stigma ...
- Older Veterans with cognitive difficulties could mistakenly be diagnosed with Alzheimer's when PTSD is root causeon May 9, 2024 at 12:36 pm
A new study has investigated how measures of thinking, memory, and Alzheimer's disease risk group together in Veterans aged 65 and older without dementia. Results of the study showed multiple patterns ...
- Governor Stitt signs PTSD bill: A victory for police mental healthon May 9, 2024 at 8:11 am
Governor Kevin Stitt signed new post-traumatic stress disorder (PTSD) bill, SB 1457, into law for the Oklahoma Fraternal Order of Police (OK FOP).This bill woul ...
- Investors Warm Up to Psychedelics as FDA Reviews Treatment for PTSDon May 9, 2024 at 5:40 am
Plus, a key decision expected this summer from the US Food and Drug Administration on whether to authorize MDMA (also known as ecstasy) to treat PTSD could help push investment in the industry more ...
- Psychedelic Toad Venom Shows Promise for New Depression Treatmenton May 8, 2024 at 12:00 pm
Scientists have mapped the structure of a psychedelic drug derived from the Colorado River toad, which seems to have antidepressant effects.
- The FDA could approve MDMA therapy for PTSD treatmenton May 8, 2024 at 5:39 am
As a means to help those with post-traumatic stress disorder, a Food and Drug Administration panel of independent advisers will discuss whether or not MDMA-assisted therapy should be approved for a ...
- Air Force Pilots Now Can Start Mental Health Treatment and Won't Immediately Be Pulled from Flight Statuson May 7, 2024 at 3:50 pm
Prior to the policy update, which was publicized in a May 1 press release, if an airman began seeking treatment for mental health-related illnesses or concerns, they would then need a return-to-duty ...
- Postpartum PTSD: Right Diagnosis Can Help Mothers and Babieson May 7, 2024 at 12:39 pm
“A woman may feel like she has failed for not being able to have a vaginal delivery,” Dekel said. “In some cases, postpartum PTSD can also become a disincentive for future pregnancy. It leads to ...
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatmenton May 7, 2024 at 12:46 am
The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to reach $27.37 billion by 2033, according to Future Market Insights. Existing treatment options like SSRIs and SNRIs ...
- Pharmalittle: We’re reading about MDMA for PTSD, a CRISPR treatment for blindness, and moreon May 6, 2024 at 4:59 pm
This would be the first FDA panel of outside experts to review a potential new PTSD treatment in 25 years. After decades of studies, psychoactive ingredients, whether derived from cannabis, LSD, or ...
via Bing News